0.3338
前日終値:
$0.333
開ける:
$0.3052
24時間の取引高:
4.03M
Relative Volume:
0.95
時価総額:
$9.29M
収益:
-
当期純損益:
$-22.71M
株価収益率:
-0.0285
EPS:
-11.71
ネットキャッシュフロー:
$-18.24M
1週間 パフォーマンス:
+21.38%
1か月 パフォーマンス:
+19.21%
6か月 パフォーマンス:
-69.38%
1年 パフォーマンス:
-86.21%
Genprex Inc Stock (GNPX) Company Profile
GNPX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
GNPX
Genprex Inc
|
0.3338 | 7.65M | 0 | -22.71M | -18.24M | -11.71 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2021-01-26 | 開始されました | National Securities | Buy |
2019-04-29 | 開始されました | Noble Capital Markets | Outperform |
Genprex Inc (GNPX) 最新ニュース
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting | GNPX Stock News - GuruFocus
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - PR Newswire
Genprex Collaborators Present Positive Preclinical Data on Diabe - GuruFocus
Genprex (GNPX) Reports Promising Preclinical Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - StreetInsider
What Can Genprex Inc (NASDAQ: GNPX) Expect In 2025? - Stocksregister
WestPark Capital Leads Placement for GNPX | GNPX Stock News - GuruFocus
Genprex (GNPX) to Release Quarterly Earnings on Wednesday - Defense World
Things To Consider Before Buying Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes - BioWorld MedTech
Attention Investors: What’s Really Going On With Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex Announces Research Agreement for Diabetes Therapy - TipRanks
Genprex (GNPX) Advances Diabetes Therapy Research with New Agreement | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - PR Newswire
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy - GuruFocus
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy | GNPX Stock News - GuruFocus
Genprex Secures Exclusive Patent License for Reqorsa - TipRanks
Genprex Signs Exclusive License to Additional Gene Therapy Techn - GuruFocus
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma | GNPX Stock News - GuruFocus
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma - PR Newswire
Geode Capital Management LLC Grows Position in Genprex, Inc. (NASDAQ:GNPX) - Defense World
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - ADVFN
Genprex collaborators report positive preclinical data on the use of Reqorsa gene therapy at the 2025 AACR Annual Meeting - SelectScience
Genprex Inc (NASDAQ: GNPX) Is The Number One Stock Currently Moving. - Stocksregister
Genprex (GNPX) Showcases Promising Results for Reqorsa Gene Ther - GuruFocus
Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy - TradingView
Genprex Collaborators Report Positive Preclinical Data on the Us - GuruFocus
Financial Metrics Check: Genprex Inc (GNPX)’s Ratios for Trailing Twelve Months - DWinneX
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - The Malaysian Reserve
Genprex Collaborators to Present Positive Preclinical Data on Di - GuruFocus
Taking the lead: Genprex Inc (GNPX) - Sete News
Understanding the Risks of Investing in Genprex Inc (GNPX) - knoxdaily.com
Genprex (GNPX) Secures Exclusive Patent License for Mesothelioma - GuruFocus
Indo-Asian News Service - Indo-Asian News Service (IANS)
Genprex secures exclusive license for mesothelioma gene therapy By Investing.com - Investing.com South Africa
Genprex secures exclusive license for mesothelioma gene therapy - Investing.com Australia
Choosing between riding the trend or protecting profits: Genprex Inc (GNPX) - uspostnews.com
Genprex Inc (NASDAQ: GNPX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Genprex Signs Exclusive Technology License Agreement with New Yo - GuruFocus
Genprex (GNPX) Secures Exclusive License for Gene Therapy Patent - GuruFocus
Genprex Signs Agreement With New York University Langone Health - marketscreener.com
Revolutionary Gene Therapy Shows 84% Target Success in Mesothelioma Treatment: Genprex-NYU Partnership - Stock Titan
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma - The Malaysian Reserve
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Grows By 487.6% - Defense World
Stock Market Recap: Genprex Inc (GNPX) Concludes at 0.27, a 0.57 Surge/Decline - DWinneX
GNPXGenprex Inc Latest Stock News & Market Updates - Stock Titan
GNPX’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Now Is The Time To Build A Position In Genprex Inc (NASDAQ:GNPX) - Marketing Sentinel
Genprex Selected to Present Trial Design of Acclaim-3 Clinical T - GuruFocus
Genprex Inc (GNPX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):